Upcoming IBD Studies


CADHUM calprotectin-directed HUMIRA® maintenance therapy, a double-blind, double-dummy, randomized trial in Crohn's disease

Principal Investigator: Peter Higgins, MD, PhD, MSc

This prospective study has been proposed by the study team to Abbott Laboratories to determine whether Crohn's patients in remission, with a fecal calprotectin <167, can safely stop Humira® therapy for up to 48 weeks, and if this state can be safely monitored with biomarkers of inflammation with no further therapy. If and when elevations in biologic biomarkers occur, Humira® therapy will be restarted as needed.


Contact person: